Study of Motexafin Gadolinium for the Treatment of Renal Cell (Kidney) Cancer

Study Identifier
PCYC-0219
CT.gov Identifier
NCT00134186
EudraCT Identifier
Not available
EUCTIS ID
Not available
For general inquiries, please contact

844-663-3742 or [email protected]

Study Complete

Study Details

Medical Condition
  • Cancer - Other
  • Genitourinary Cancer - Other
    • Study Drug
  • motexafin gadolinium
    • Phase
    Phase 2
    Sex
    Female & Male
    Age
    18+ years
    Inclusion and Exclusion Criteria
    Inclusion Criteria:
    * ≥ 18 years old * Histologically confirmed renal cell carcinoma with clinically or pathologically confirmed progression * Ineligible for interleukin-2 (IL-2) treatment and/or have had 2 or fewer prior treatments * Measurable disease * Hemoglobin ≥ 9 mg/dL * ECOG performance status of 0, 1, or 2 * Willing and able to provide written informed consent
    Exclusion Criteria:
    * Inadequate bone marrow, renal and liver function by laboratory criteria * Absolute neutrophil count \< 1500/µL; * Platelet count \< 100,000/µL; * AST or ALT \> 2 x upper limit of normal (ULN); * Alkaline phosphatase \> 5 x ULN; * Total bilirubin \> 2 x ULN; * Creatinine \> 2.0 mg/dL. * Evidence of central nervous system metastases within past year * Uncontrolled hypertension * Known history of porphyria, G6PD deficiency or HIV

    Protocol Summary

    The purpose of this study is to find out if renal cell (kidney) cancer that has spread to other parts of the body will respond to treatment with motexafin gadolinium (MGd).

    Study Locations

    Location
    Status
    Location
    Methodist Hospital
    Houston, Texas, United States, 77030
    Status
    Not applicable